News & Events

Date Title  
11/15/18
Clinical results presented from over 1,300 patients treated at 108 sites with Obalon’s non-surgical weight loss solution in commercial setting SAN DIEGO , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and
11/07/18
Clinical results from over 1,300 patients at 108 sites treated with Obalon’s novel weight loss device solution in commercial use SAN DIEGO , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA
11/06/18
SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang ,
11/02/18
SAN DIEGO , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial
10/23/18
SAN DIEGO, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to
10/09/18
SAN DIEGO , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces the appointment of Daina
09/26/18
SAN DIEGO , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced approval of a
08/29/18
SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to host a
08/27/18
SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has closed its
08/23/18
SAN DIEGO , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN) a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into
08/07/18
SAN DIEGO , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang ,
08/02/18
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial
08/02/18
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the promotion of Kelly Huang to the position of President, effective August 2 , 2018.   “Kelly will take a larger role in the daily operations of Obalon,” said Andy Rasdal , CEO.  “He will now have
07/24/18
SAN DIEGO , July 24, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release
06/06/18
No Reports of Deaths Related to Use of Obalon Six-Month Balloon System SAN DIEGO , June 06, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled
06/05/18

SAN DIEGO , June 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang , Chief

05/17/18

SAN DIEGO , May 17, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal , Chief

05/10/18

SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial

05/07/18

SAN DIEGO , May 07, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that Todd Wood has joined as Vice President Global Sales. Mr. Wood will be responsible for leading field sales, product specialists, sales

05/04/18

SAN DIEGO , May 04, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release

03/05/18
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial
03/05/18
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release
02/20/18
Company to Host Conference Call Today at 6:00 a.m. PST/ 9:00 a.m. EST SAN DIEGO , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today announced the Audit Committee has completed its investigation into a purported whistleblower complaint and concluded that the allegations
01/23/18
SAN DIEGO , Jan. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (the “Company” or “Obalon”) (NASDAQ:OBLN) today announced the termination of the underwriting agreement and cancellation of its previously announced public offering (the “Offering”) of 5,454,545 shares of its common stock at a
01/18/18
SAN DIEGO , Jan. 18, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced the pricing of an underwritten
01/16/18
SAN DIEGO , Jan. 16, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced that it is commencing an
01/05/18
SAN DIEGO , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today reported that it achieved preliminary, unaudited revenue of approximately $3.9 million for the fourth quarter ended December 31, 2017 , an estimated increase of approximately 400% over the fourth quarter of
01/04/18
SAN DIEGO , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling